Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

IKT - Inhibikase Therapeutics Inc Stock Price, Fair Value and News

$2.22+0.02 (+0.91%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

IKT Price Action

Last 7 days

13.3%

Last 30 days

-1.8%

Last 90 days

-35.5%

Trailing 12 Months

4.2%

IKT Stock Price

Mar'24Jun'24Sep'24Dec'241234
$2.22

IKT RSI Chart

JunJulAugSepOctNovDec2025FebMar102030405060708090

IKT Valuation

Market Cap

149.2M

Price/Earnings (Trailing)

-7.62

Price/Sales (Trailing)

608.73

Price/Free Cashflow

-9.19

IKT Price/Sales (Trailing)

20222023202402004006008001K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IKT Fundamentals

IKT Revenue

Revenue (TTM)

260.5K

202020212022202320240500K1M1.5M2M2.5M3M3.5M

IKT Earnings

Earnings (TTM)

-19.6M

Earnings Growth (Yr)

-25.74%

Earnings Growth (Qtr)

-16.5%

2005201020152020-20M-15M-10M-5M

IKT Profitability

Return on Equity

3.7K%

Return on Assets

-447.01%

Free Cashflow Yield

-10.88%

IKT Investor Care

Shares Dilution (1Y)

988.27%

Diluted EPS (TTM)

-2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20202021202220230500K1M1.5M2M2.5M3M3.5M
Net sales
YearQ1Q2Q3Q4
20240000
2023141.9K251.8K324.1K260.5K
20222.4M1.6M867.7K123.4K
20211.8M3.0M3.3M3.1M
20201.0M910.6K804.5K698.5K
20190001.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
 CEO
 WEBSITEinhibikase.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Inhibikase Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Inhibikase Therapeutics Inc? What does IKT stand for in stocks?

IKT is the stock ticker symbol of Inhibikase Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inhibikase Therapeutics Inc (IKT)?

As of Fri Mar 14 2025, market cap of Inhibikase Therapeutics Inc is 149.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IKT stock?

You can check IKT's fair value in chart for subscribers.

Is Inhibikase Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether IKT is over valued or under valued. Whether Inhibikase Therapeutics Inc is cheap or expensive depends on the assumptions which impact Inhibikase Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IKT.

What is Inhibikase Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 14 2025, IKT's PE ratio (Price to Earnings) is -7.62 and Price to Sales (PS) ratio is 608.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKT PE ratio will change depending on the future growth rate expectations of investors.